Cellegy Contraception Gel Study Continues After Firm Drops HIV Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III Nigerian trial was halted after data monitoring committee determines the microbicide was unlikely to show convincing evidence it protects against HIV.
You may also be interested in...
Cellegy Seeks A Buyer Or Partner For Cellegesic Following FDA “Approvable” Letter
"Approvable" letter indicates the need for additional studies to provide more evidence of the efficacy of the nitroglycerin ointment for anal fissures.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.